In a 60-week open-label extension of 159 Japanese adults with chronic migraine, eptinezumab every 12 weeks showed no new safety signals (serious adverse events 3.1%, withdrawals 4.4%); just over 35% had ≥50% fewer monthly migraine days from week 24.
RCTn = 159
Takeshima et al. Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial